

STANDARD OPERATING PROCEDURES

RESPONDING TO A POLIOVIRUS EVENT OR OUTBREAK

Version 4

March 2022



STANDARD OPERATING PROCEDURES RESPONDING TO A POLIOVIRUS EVENT OR OUTBREAK

Version 4

March 2022



Standard operating procedures: responding to a poliovirus event or outbreak, version 4

ISBN 978-92-4-004915-4 (electronic version)

ISBN 978-92-4-004916-1 (print version)

Published by the World Health Organization (WHO) on behalf of the Global Polio Eradication Initiative

© World Health Organization 2022

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. Standard operating procedures: responding to a poliovirus event or outbreak, version 4 Geneva: World Health Organization; 2022. Licence: [CC BY-NC-SA 3.0 IGO](#).

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/copyright>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

CONTENTS

Acknowledgement	iv
Acronyms	v
1. Overview	1
Background	1
Purpose and scope	1
What's new in this version	2
Related Guidance	4
Polio Eradication Strategy 2022–2026, Delivering on a Promise	4
2. Poliovirus events & OutBreaks	7
Key Definitions:	7
Definition of Polio Outbreaks and Events in this version of the SOPs	8
3. Detection, notification & investigation .11	
Detection	11
Notification	11
Investigation	12
4. Risk assessment	19
Initial risk assessment	19
Including sentinel events in the risk assessment	22
Ongoing risk assessment	22
5. Response standards - overview.	23
Minimum response standards for poliovirus events and outbreaks	23
Outbreak grading	24
Standard timelines for outbreak response	25
6. Vaccination Response	27
Oral polio vaccine (OPV) for Outbreak Response	27
Initiation	28
Concurrent circulation of different poliovirus types	34
Vaccine Choice	35
High-quality campaigns	35
Integration with other health interventions	38
Continued adaptation to the COVID-19 pandemic	38
Inactivated polio vaccine (IPV)	38
Requesting vaccine	39
Routine immunization coverage improvement planning, to be integral part of polio outbreak response	41
7. Surveillance following investigation . .43	
Surveillance enhancement	43
Environmental surveillance	44
Strategies for special populations and security-compromised areas	46
8. Communication and social mobilization 47	
Strategic C4D framework for polio outbreak response	47
Data gathering to guide C4D activities . .	48
Communication strategies	49
9. GPEI Support	51
Coordination	52
Budgets and financing	52
Human resource surge	53
GPEI performance standards	54
10. Monitoring and Evaluation of response 55	
Monitoring quality of SIAs	55
Monitoring surveillance enhancement . .	57
Novel OPV2 post deployment monitoring	58
Outbreak response assessments (OBRA)s	58
11. Gender Mainstreaming	61
12. Prevention of sexual exploitation, abuse and harassment	63
Annexes	65
Annex 1: Risk assessment overview . . .	65
Annex 2: Timeline and responsibility . .	67
Annex 3: Gender Checklist for Polio Outbreak Response	78
Annex 3: Gender Checklist for Polio Outbreak Response	78
References.	79

ACKNOWLEDGEMENT

This document reflects inputs and contributions from epidemiologists, technical experts, laboratory scientists, public health and gender experts from field, regional and global levels, in a process led by the GPEI partners: Rotary International, World Health Organization, the US Centers for Disease Control and Prevention, the United Nations Children's Fund, the Bill & Melinda Gates Foundation, and Gavi, the Vaccine Alliance. Some critical aspects of these SOPs were derived from broad consultations with expert advisory groups, including the WHO, Strategic Advisory Group of Experts (SAGE) on immunization and endorsed by the GPEI's relevant technical and management groups.

ACRONYMS

AFP	Acute Flaccid Paralysis	NPAFP	Non Polio Acute Flaccid Paralysis
aVDPV	Ambiguous Vaccine Derived Poliovirus	OBRA	Outbreak Response Assessment
bOPV	Bivalent Oral Polio Vaccine	OPV	Oral Polio Vaccine
COVID-19	Coronavirus Disease 2019	ORPG	Outbreak Response and Preparedness Group
cVDPV	Circulating Vaccine Derived Poliovirus	PCS	Post Certification Strategy
DG	Director General	PHEIC	Public Health Emergency of International Concern
DON	Disease Outbreak Notification	PID	Primary immunodeficiency disorder
EOC	Emergency Operation Centre	PIRI	Periodic Intensification of Routine Immunization
EPI	Expanded Programme on Immunization	POB	Polio Oversight Board
ES	Environmental Sampling	PRSEAH	Prevention of Sexual Exploitation, Abuse and Harassment
EUL	Emergency Use Listing	RED	Reach Every District
EV	Enterovirus	RR	Rapid Response
GAVI	Global Alliance for Vaccines and Immunizations	RRT	Rapid Response Team
GIS	Geographic Information System	SAGE	Strategic Advisory Group of Expert on Immunization
GPEI	Global Polio Eradication Initiative	SIA	Supplementary Immunization Activities
GPLN	Global Polio Laboratory Network	SIAD	Short Interval Additional Dose Strategy
GPS	Global Positioning System	STOP	Stop Transmission of Polioviruses
IHR	International Health Regulations	tOPV	Trivalent Oral Polio Vaccine
IM	Independent Monitoring	UNDSS	United Nations Department of Safety and Security
IMST	Incident Management Support Team	UNICEF	United Nations Children's Fund
IPC	Infection Prevention and Control	VAPP	Vaccine Associated Paralytic Polio
IPV	Inactivated Polio Vaccine	VDPV	Vaccine Derived Poliovirus
iVDPV	Immunodeficiency-associated Vaccine Derived Poliovirus	VVM	Vaccine Vial Monitor
LQAS	Lot quality Assurance Sampling	WHO	World Health Organization
mOPV2	Monovalent Oral Polio Vaccine type2	WPV	Wild Poliovirus
nOPV2	Novel Oral Polio Vaccine type2		

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_31907

